Recent advance in antigen-specific immunotherapy for acute myeloid leukemia

Clinical and Developmental Immunology

Volumn 2011, Issue , 2011, Pages

  Kadowaki, Norimitsu ^a   Kitawaki, Toshio ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AURORA A KINASE; CALCINEURIN INHIBITOR; CANCER VACCINE; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; FLUDARABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HLA A ANTIGEN; LEUKEMIA ANTIGEN; MYELOBLASTIN; PEPTIDE VACCINE; T LYMPHOCYTE RECEPTOR; TELOMERASE REVERSE TRANSCRIPTASE; WT1 PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; SUBUNIT VACCINE; TUMOR ANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE TRANSFER; ALLOTRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; CANCER CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER REGRESSION; CANCER RESISTANCE; CANCER SURVIVAL; CD8+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL EFFECTIVENESS; CYTOTOXIC T LYMPHOCYTE; GERIATRIC PATIENT; GRAFT VERSUS HOST REACTION; HAPLOTYPE; HUMAN; IMMUNOGENICITY; LEUKEMIA RELAPSE; LEUKEMOGENESIS; MINIMAL RESIDUAL DISEASE; MONOCYTE; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; DENDRITIC CELL; DRUG THERAPY; GENETIC ENGINEERING; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; METHODOLOGY; T LYMPHOCYTE; TRANSPLANTATION;

ANTIGENS, NEOPLASM; CTLA-4 ANTIGEN; DENDRITIC CELLS; DRUG THERAPY; GENETIC ENGINEERING; HUMANS; IMMUNOTHERAPY; LEUKEMIA, MYELOID, ACUTE; T-LYMPHOCYTES; VACCINES, SUBUNIT;

EID: 84855166689     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2011/104926     Document Type: Review

References (63)

1. Ishikawa F., Yoshida S., Saito Y., Hijikata A., Kitamura H., Tanaka S., Nakamura R., Tanaka T., Tomiyama H., Saito N., Fukata M., Miyamoto T., Lyons B., Ohshima K., Uchida N., Taniguchi S., Ohara O., Akashi K., Harada M., Shultz L. D., Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region Nature Biotechnology 2007 25 11 1315 1321 (Pubitemid 350076512)
2. Menzin J., Lang K., Earle C. C., Kerney D., Mallick R., The outcomes and costs of acute myeloid leukemia among the elderly Archives of Internal Medicine 2002 162 14 1597 1603 (Pubitemid 34773427)
3. Ohminami H., Yasukawa M., Fujita S., HLA class I-restricted lysis of leukemia cells by a CD8+ cytotoxic T- lymphocyte clone specific for WT1 peptide Blood 2000 95 1 286 293 (Pubitemid 30017254)
4. Gao L., Bellantuono I., Elssser A., Marley S. B., Gordon M. Y., Goldman J. M., Stauss H. J., Selective elimination of leukemic CD34+ progenitor cells by cytotoxic T lymphocytes specific for WT1 Blood 2000 95 7 2198 2203 (Pubitemid 30167714)
5. Inoue K., Tamaki H., Ogawa H., Oka Y., Soma T., Tatekawa T., Oji Y., Tsuboi A., Kim E. H., Kawakami M., Akiyama T., Kishimoto T., Sugiyama H., Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells Blood 1998 91 8 2969 2976 (Pubitemid 28227548)
6. Gaiger A., Reese V., Disis M. L., Cheever M. A., Immunity to WT1 in the animal model and in patients with acute myeloid leukemia Blood 2000 96 4 1480 1489 (Pubitemid 30658480)
7. Elisseeva O. A., Oka Y., Tsuboi A., Ogata K., Wu F., Kim E. H., Soma T., Tamaki H., Kawakami M., Oji Y., Hosen N., Kubota T., Nakagawa M., Yamagami T., Hiraoka A., Tsukaguchi M., Udaka K., Ogawa H., Kishimoto T., Nomura T., Sugiyama H., Humoral immune responses against Wilms tumor gene WT1 product in patients with hematopoietic malignancies Blood 2002 99 9 3272 3279 (Pubitemid 34525307)
8. Scheibenbogen C., Letsch A., Thiel E., Schmittel A., Mailaender V., Baerwolf S., Nagorsen D., Keilholz U., CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia Blood 2002 100 6 2132 2137 (Pubitemid 35001248)
9. Rezvani K., Grube M., Brenchley J. M., Sconocchia G., Fujiwara H., Price D. A., Gostick E., Yamada K., Melenhorst J., Childs R., Hensel N., Douek D. C., Barrett A. J., Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation Blood 2003 102 8 2892 2900 (Pubitemid 37248862)
10. Rezvani K., Yong A. S. M., Savani B. N., Mielke S., Keyvanfar K., Gostick E., Price D. A., Douek D. C., Barrett A. J., Graft-versus-leukemia effects associated with detectable Wilms tumor-1-specific T lymphocytes after allogeneic stem-cell transplantation for acute lymphoblastic leukemia Blood 2007 110 6 1924 1932 (Pubitemid 47443906)
11. Molldrem J., Dermime S., Parker K., Jiang Y. Z., Mavroudis D., Hensel N., Fukushima P., Barrett A. J., Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells Blood 1996 88 7 2450 2457 (Pubitemid 26327493)
12. Molldrem J. J., Lee P. P., Wang C., Felio K., Kantarjian H. M., Champlin R. E., Davis M. M., Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia Nature Medicine 2000 6 9 1018 1023
13. Greiner J., Li L., Ringhoffer M., Barth T. F. E., Giannopoulos K., Guillaume P., Ritter G., Wiesneth M., Dhner H., Schmitt M., Identification and characterization of epitopes of the receptor for hyaluronic acid-mediated motility (RHAMM/CD168) recognized by CD8+ T cells of HLA-A2-positive patients with acute myeloid leukemia Blood 2005 106 3 938 945 (Pubitemid 41076438)
14. Arai J., Yasukawa M., Ohminami H., Kakimoto M., Hasegawa A., Fujita S., Identification of human telomerase reverse transcriptase-derived peptides that induce HLA-A24-restricted antileukemia cytotoxic T lymphocytes Blood 2001 97 9 2903 2907
15. Morita Y., Heike Y., Kawakami M., Miura O., Nakatsuka S. I., Ebisawa M., Mori S. I., Tanosaki R., Fukuda T., Kim S. W., Tobinai K., Takaue Y., Monitoring of WT1-specific cytotoxic T lymphocytes after allogeneic hematopoietic stem cell transplantation International Journal of Cancer 2006 119 6 1360 1367 (Pubitemid 44258812)
16. Rezvani K., Yong A. S. M., Tawab A., Jafarpour B., Eniafe R., Mielke S., Savani B. N., Keyvanfar K., Li Y., Kurlander R., Barrett A. J., Ex vivo characterization of polyclonal memory CD8+ T-cell responses to PRAME-specific peptides in patients with acute lymphoblastic leukemia and acute and chronic myeloid leukemia Blood 2009 113 10 2245 2255
17. Ochi T., Fujiwara H., Suemori K., Azuma T., Yakushijin Y., Hato T., Kuzushima K., Yasukawa M., Aurora-A kinase: a novel target of cellular immunotherapy for leukemia Blood 2009 113 1 66 74
18. Saito Y., Kitamura H., Hijikata A., Tomizawa-Murasawa M., Tanaka S., Takagi S., Uchida N., Suzuki N., Sone A., Najima Y., Ozawa H., Wake A., Taniguchi S., Shultz L. D., Ohara O., Ishikawa F., Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells Science Translational Medicine 2010 2 17 17 ra9
19. Oka Y., Tsuboi A., Taguchi T., Osaki T., Kyo T., Nakajima H., Elisseeva O. A., Oji Y., Kawakami M., Ikegame K., Hosen N., Yoshihira S., Wu F., Fujiki F., Murakami M., Masuda T., Nishida S., Shirakata T., Nakatsuka S. I., Sasaki A., Udaka K., Dohy H., Aozasa K., Noguchi S., Kawase I., Sugiyama H., Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression Proceedings of the National Academy of Sciences of the United States of America 2004 101 38 13885 13890 (Pubitemid 39298502)
20. Oka Y., Tsuboi A., Murakami M., Hirai M., Tominaga N., Nakajima H., Elisseeva O. A., Masuda T., Nakano A., Kawakami M., Oji Y., Ikegame K., Hosen N., Udaka K., Yasukawa M., Ogawa H., Kawase I., Sugiyama H., Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis International Journal of Hematology 2003 78 1 56 61 (Pubitemid 36899903)
21. Keilholz U., Letsch A., Busse A., Asemissen A. M., Bauer S., Blau I. W., Hofmann W. K., Uharek L., Thiel E., Scheibenbogen C., A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS Blood 2009 113 26 6541 6548
22. Rezvani K., Yong A. S. M., Mielke S., Savani B. N., Musse L., Superata J., Jafarpour B., Boss C., Barrett A. J., Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies Blood 2008 111 1 236 242
23. Maslak P. G., Dao T., Krug L. M., Chanel S., Korontsvit T., Zakhaleva V., Zhang R., Wolchok J. D., Yuan J., Pinilla-Ibarz J., Berman E., Weiss M., Jurcic J., Frattini M. G., Scheinberg D. A., Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia Blood 2010 116 2 171 179
24. May R. J., Dao T., Pinilla-Ibarz J., Korontsvit T., Zakhaleva V., Zhang R. H., Maslak P., Scheinberg D. A., Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4 + and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells Clinical Cancer Research 2007 13 15 4547 4555 (Pubitemid 47219725)
25. Melief C. J. M., Van Der Burg S. H., Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines Nature Reviews Cancer 2008 8 5 351 360 (Pubitemid 351589701)
26. Bijker M. S., van den Eeden S. J. F., Franken K. L., Melief C. J. M., van der Burg S. H., Offringa R., Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation European Journal of Immunology 2008 38 4 1033 1042
27. Schmitt M., Schmitt A., Rojewski M. T., Chen J., Giannopoulos K., Fei F., Yu Y., Gtz M., Heyduk M., Ritter G., Speiser D. E., Gnjatic S., Guillaume P., Ringhoffer M., Schlenk R. F., Liebisch P., Bunjes D., Shiku H., Dohner H., Greiner J., RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses Blood 2008 111 3 1357 1365 (Pubitemid 351213422)
28. Borrello I. M., Levitsky H. I., Stock W., Sher D., Qin L., DeAngelo D. J., Alyea E. P., Stone R. M., Damon L. E., Linker C. A., Maslyar D. J., Hege K. M., Granulocyte-macrophage colony-stimulating factor (GM-CSF)-secreting cellular immunotherapy in combination with autologous stem cell transplantation (ASCT) as postremission therapy for acute myeloid leukemia (AML) Blood 2009 114 9 1736 1745
29. Ho V. T., Vanneman M., Kim H., Sasada T., Yoon J. K., Pasek M., Cutler C., Koreth J., Alyea E., Sarantopoulos S., Antin J. H., Ritz J., Canning C., Kutok J., Mihm M. C., Dranoff G., Soiffer R., Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation Proceedings of the National Academy of Sciences of the United States of America 2009 106 37 15825 15830
30. Fujii S. I., Shimizu K., Fujimoto K., Kiyokawa T., Tsukamoto A., Sanada I., Kawano F., Treatment of post-transplanted, relapsed patients with hematological malignancies by infusion of HLA-matched, allogeneic-dendritic cells (DCs) pulsed with irradiated tumor cells and primed T cells Leukemia and Lymphoma 2001 42 3 357 369 (Pubitemid 32725591)
31. Li L., Giannopoulos K., Reinhardt P., Tabarkiewicz J., Schmitt A., Greiner J., Rolinski J., Hus I., Dmoszynska A., Wiesneth M., Schmitt M., Immunotherapy for patients with acute myeloid leukemia using autologous dendritic cells generated from leukemic blasts International Journal of Oncology 2006 28 4 855 861
32. Roddie H., Klammer M., Thomas C., Thomson R., Atkinson A., Sproul A., Waterfall M., Samuel K., Yin J., Johnson P., Turner M., Phase I/II study of vaccination with dendritic-like leukaemia cells for the immunotherapy of acute myeloid leukaemia The British Journal of Haematology 2006 133 2 152 157
33. Draube A., Beyer M., Wolf J., Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells European Journal of Haematology 2008 81 4 281 288
34. Lee J. J., Kook H., Park M. S., Nam J. H., Choi B. H., Song W. H., Park K. S., Lee I. K., Chung I. J., Hwang T. J., Kim H. J., Immunotherapy using autologous monocyte-derived dendritic cells pulsed with leukemic cell lysates for acute myeloid leukemia relapse after autologous peripheral blood stem cell transplantation Journal of Clinical Apheresis 2004 19 2 66 70 (Pubitemid 39006610)
35. Van Tendeloo V. F., Van De Veldea A., Van Driesschea A., Coolsa N., Anguille S., Ladell K., Gostick E., Vermeulen K., Pieters K., Nijs G., Stein B., Smits E. L., Schroyens W. A., Gadisseur A. P., Vrelust I., Jorens P. G., Goossens H., De Vries I. J., Price D. A., Oji Y., Oka Y., Sugiyama H., Berneman Z. N., Induction of complete and molecular remissions in acute myeloid leukemia by Wilms' tumor 1 antigen-targeted dendritic cell vaccination Proceedings of the National Academy of Sciences of the United States of America 2010 107 31 13824 13829
36. Kitawaki T., Kadowaki N., Fukunaga K., Cross-priming of CD8+ T cells in vivo by dendritic cells pulsed with autologous apoptotic leukemic cells in immunotherapy for elderly patients with acute myeloid leukemia Experimental Hematology 2011 39 4 424.e2 433.e2
37. Kitawaki T., Kadowaki N., Fukunaga K., A phase I/IIa clinical trial of immunotherapy for elderly patients with acute myeloid leukaemia using dendritic cells co-pulsed with WT1 peptide and zoledronate The British Journal of Haematology 2011 153 6 796 799
38. Theobald M., Biggs J., Hernndez J., Lustgarten J., Labadie C., Sherman L. A., Tolerance to p53 by A2.1-restricted cytotoxic T lymphocytes Journal of Experimental Medicine 1997 185 5 833 841 (Pubitemid 27119867)
39. Finn O. J., Molecular origins of cancer: cancer immunology The New England Journal of Medicine 2008 358 25 2704 2715 (Pubitemid 351860863)
40. Rosenberg S. A., Yannelli J. R., Yang J. C., Topalian S. L., Schwartzentruber D. J., Weber J. S., Parkinson D. R., Seipp C. A., Einhorn J. H., White D. E., Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2 Journal of the National Cancer Institute 1994 86 15 1159 1166 (Pubitemid 24249302)
41. Morgan R. A., Dudley M. E., Wunderlich J. R., Hughes M. S., Yang J. C., Sherry R. M., Royal R. E., Topalan S. L., Kammula U. S., Restifo N. P., Zheng Z., Nahvi A., De Vries C. R., Rogers-Freezer L. J., Mavroukakis S. A., Rosenberg S. A., Cancer regression in patients after transfer of genetically engineered lymphocytes Science 2006 314 5796 126 129 (Pubitemid 44547756)
42. Johnson L. A., Morgan R. A., Dudley M. E., Cassard L., Yang J. C., Hughes M. S., Kammula U. S., Royal R. E., Sherry R. M., Wunderlich J. R., Lee C. C. R., Restifo N. P., Schwarz S. L., Cogdill A. P., Bishop R. J., Kim H., Brewer C. C., Rudy S. F., VanWaes C., Davis J. L., Mathur A., Ripley R. T., Nathan D. A., Laurencot C. M., Rosenberg S. A., Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen Blood 2009 114 3 535 546
43. Parkhurst M. R., Yang J. C., Langan R. C., Dudley M. E., Nathan D. A. N., Feldman S. A., Davis J. L., Morgan R. A., Merino M. J., Sherry R. M., Hughes M. S., Kammula U. S., Phan G. Q., Lim R. M., Wank S. A., Restifo N. P., Robbins P. F., Laurencot C. M., Rosenberg S. A., T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis Molecular Therapy 2010 19 3 620 226
44. Tsuji T., Yasukawa M., Matsuzaki J., Ohkuri T., Chamoto K., Wakita D., Azuma T., Niiya H., Miyoshi H., Kuzushima K., Oka Y., Sugiyama H., Ikeda H., Nishimura T., Generation of tumor-specific, HLA class I-restricted human Th1 and Tc1 cells by cell engineering with tumor peptide-specific T-cell receptor genes Blood 2005 106 2 470 476 (Pubitemid 40981240)
45. Xue S. A., Gao L., Hart D., Gillmore R., Qasim W., Thrasher A., Apperley J., Engels B., Uckert W., Morris E., Stauss H., Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells Blood 2005 106 9 3062 3067 (Pubitemid 41565901)
46. Xue S. A., Gao L., Thomas S., Hart D. P., Xue J. Z., Gillmore R., Voss R. H., Morris E., Stauss H. J., Development of a Wilms' tumor antigen-specific T-cell receptor for clinical trials: engineered patient's T cells can eliminate autologous leukemia blasts in NOD/SCID mice Haematologica 2010 95 1 126 134
47. Ochi T., Fujiwara H., Okamoto S., Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked anti-leukemia reactivity and safety Blood 2011 118 6 1495 1503
48. Schmitt T. M., Ragnarsson G. B., Greenberg P. D., T cell receptor gene therapy for cancer Human Gene Therapy 2009 20 11 1240 1248
49. Bendle G. M., Linnemann C., Hooijkaas A. I., Bies L., De Witte M. A., Jorritsma A., Kaiser A. D. M., Pouw N., Debets R., Kieback E., Uckert W., Song J. Y., Haanen J. B. A. G., Schumacher T. N. M., Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy Nature Medicine 2010 16 5 565 570
50. Okamoto S., Mineno J., Ikeda H., Fujiwara H., Yasukawa M., Shiku H., Kato I., Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR Cancer Research 2009 69 23 9003 9011
51. Kochenderfer J. N., Wilson W. H., Janik J. E., Dudley M. E., Stetler-Stevenson M., Feldman S. A., Maric I., Raffeld M., Nathan D. A. N., Lanier B. J., Morgan R. A., Rosenberg S. A., Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19 Blood 2010 116 20 4099 4102
52. Morgan R. A., Yang J. C., Kitano M., Dudley M. E., Laurencot C. M., Rosenberg S. A., Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2 Molecular Therapy 2010 18 4 843 851
53. Brentjens R., Yeh R., Bernal Y., Riviere I., Sadelain M., Treatment of chronic lymphocytic leukemia with genetically targeted autologous t cells: case report of an unforeseen adverse event in a phase i clinical trial Molecular Therapy 2010 18 4 666 668
54. Peinert S., Prince H. M., Guru P. M., Kershaw M. H., Smyth M. J., Trapani J. A., Gambell P., Harrison S., Scott A. M., Smyth F. E., Darcy P. K., Tainton K., Neeson P., Ritchie D. S., Hnemann D., Gene-modified T cells as immunotherapy for multiple myeloma and acute myeloid leukemia expressing the Lewis y antigen Gene Therapy 2010 17 5 678 686
55. Hodi F. S., O'Day S. J., McDermott D. F., Weber R. W., Sosman J. A., Haanen J. B., Gonzalez R., Robert C., Schadendorf D., Hassel J. C., Akerley W., Van Den Eertwegh A. J. M., Lutzky J., Lorigan P., Vaubel J. M., Linette G. P., Hogg D., Ottensmeier C. H., Lebbé C., Peschel C., Quirt I., Clark J. I., Wolchok J. D., Weber J. S., Tian J., Yellin M. J., Nichol G. M., Hoos A., Urba W. J., Improved survival with ipilimumab in patients with metastatic melanoma The New England Journal of Medicine 2010 363 8 711 723
56. Phan G. Q., Yang J. C., Sherry R. M., Hwu P., Topalian S. L., Schwartzentruber D. J., Restifo N. P., Haworth L. R., Seipp C. A., Freezer L. J., Morton K. E., Mavroukakis S. A., Duray P. H., Steinberg S. M., Allison J. P., Davis T. A., Rosenberg S. A., Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma Proceedings of the National Academy of Sciences of the United States of America 2003 100 14 8372 8377 (Pubitemid 36842552)
57. Brahmer J. R., Drake C. G., Wollner I., Powderly J. D., Picus J., Sharfman W. H., Stankevich E., Pons A., Salay T. M., McMiller T. L., Gilson M. M., Wang C., Selby M., Taube J. M., Anders R., Chen L., Korman A. J., Pardoll D. M., Lowy I., Topalian S. L., Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates Journal of Clinical Oncology 2010 28 19 3167 3175
58. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., Minato N., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade Proceedings of the National Academy of Sciences of the United States of America 2002 99 19 12293 12297
59. Ishida T., Ishii T., Inagaki A., Yano H., Komatsu H., Iida S., Inagaki H., Ueda R., Specific recruitment of CC chemokine receptor 4-positive regulatory T cells in Hodgkin lymphoma fosters immune privilege Cancer Research 2006 66 11 5716 5722 (Pubitemid 43927124)
60. Shimizu J., Yamazaki S., Sakaguchi S., Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity Journal of Immunology 1999 163 10 5211 5218
61. Morse M. A., Hobeika A. C., Osada T., Serra D., Niedzwiecki D., Kim Lyerly H., Clay T. M., Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines Blood 2008 112 3 610 618
62. Almstedt M., Blagitko-Dorfs N., Duque-Afonso J., Karbach J., Pfeifer D., Jger E., Lbbert M., The DNA demethylating agent 5-aza-2'-deoxycytidine induces expression of NY-ESO-1 and other cancer/testis antigens in myeloid leukemia cells Leukemia Research 2010 34 7 899 905
63. Goodyear O., Agathanggelou A., Novitzky-Basso I., Siddique S., McSkeane T., Ryan G., Vyas P., Cavenagh J., Stankovic T., Moss P., Craddock C., Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia Blood 2010 116 11 1908 1918